Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for Cognitive Impairment in RRMS
NCT02575365Phase 4Terminated
- Sponsor
- Novartis
- Start
- Feb 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Primary endpoint: Brief International Cognitive Assessment for Multiple Sclerosis Battery at 24 months. Started Feb 2016; status: terminated.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02575365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575365.